Calendario›PTCT›PTC124
PTC124
Ensayo de PTC THERAPEUTICS, INC. en Fibrosis quística.
Más ensayos de: Fibrosis quística.
- Fase
- Fase 2
- Estado
- Completado
- Participantes
- 19
- Centros
- 1
- Fin del objetivo primario
- jul 2007
previstos
fecha real
Título oficial en el registro (en inglés): PTC124 for the Treatment of Cystic Fibrosis
Qué significa cada fase y cada estado.
Estudio de intervención, de un solo grupo, abierto. Comenzó en dic 2006.
De principio a fin
- Empieza el ensayo (dic 2006)
- Lectura de resultados jul 2007 (real)
- Hoy
Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.
Qué mide
CFTR activity as assessed by nasal transepithelial potential difference (TEPD) (del registro, en inglés) (84 dias)
Cómo lo describe el promotor
En el documentoEn inglés, del registroIn some patients with cystic fibrosis (CF), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the cystic fibrosis transmembrane regulator (CFTR) protein. PTC124 has been shown to partially restore CFTR production in animals with CF due to a nonsense mutation. In an ongoing Phase 2a study being performed at the Hadassah University Hospital - Mount Scopus in Israel, patients with nonsense-mutation-mediated CF have received PTC124 in two 14-day treatment courses. Preliminary results from that study indicate that PTC124 has pharmacodynamic activity of PTC124 in CF and that PTC124 can be safely administered in this patient population. This Phase 2b extension study is designed to evaluate the activity and safety of 3 months (approximately 84 days) of continuous treatment with PTC124 in the same patients who were enrolled to the Phase 2a study. The main purpose of this study is to understand whether PTC124 can be safely administered and achieve pharmacodynamic activity in patients with CF due to a nonsense mutation.
Más ensayos de PTCT
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Eladocagene Exuparvovec | Fase 2 | En marcha, sin reclutar | may 2023 (real) |
| PTC844 | Fase 2 | Reclutando pacientes | sep 2027 (prevista) |
| Vatiquinone | Fase 3 | En marcha, sin reclutar | dic 2027 (prevista) |
| Vatiquinone · PROVE-FA | Fase 3 | Aún sin reclutar | mar 2029 (prevista) |
| Sepiapterin · EPIPHENY | Fase 3 | Reclutando pacientes | feb 2031 (prevista) |
| PTC923 | Fase 3 | Completado | jul 2026 (real) |
Todos los de PTCT, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT00351078), actualizada en dic 2017.